Mesna
Adrenocortical Cancer
St. Jude Children's Research HospitalSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
21 Active assets in the Adrenocortical Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Vanderbilt-Ingram Cancer Center | Phase 2 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 2 | BB |
Pembrolizumab Corcept Therapeutics | Phase 2 | B |
Nivolumab Dana-Farber Cancer Institute | Phase 2 | B |
Cyclophosphamide Anusha Kalbasi | Phase 2 | B |
View all 43 →
Same molecule, other indications
Mesna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →